What ' s known on the subject? and What does the study add? Protein kinase C inhibitor (PKCI) can decrease glomerular and tubular cell apoptosis and mitosis and attenuate collagen accumulation and fi bronectin expression in a PUUO rat model.Although the role of PKC has been well studied in diabetic nephropathy, there is no report on its role in obstructive nephropathy. This investigation evaluated the processes that were associated with the activation of PKC α and PKC β pathways and showed that PKCI played an important role in the protection of renal function during ureteric obstruction.
OBJECTIVES• To investigate the expression of the protein kinase C (PKC) pathway after partial unilateral ureteric obstruction (PUUO).• To evaluate the therapeutic potential of a PKC inhibitor (PKCI) in obstructive nephropathy.
MATERIALS AND METHODS• Thirty-six rats were divided into three groups. One sham-operated group served as the control. The other two groups received PUUO surgery, after which one group received no treatment and the other group was treated with PKCI, chelerythrine.• The severity of hydronephrosis and renal morphology were assessed: tubular and glomerularcell apoptosis, mitosis and interstitial fi brosis were examined using immunohistochemistry.• Western immunoblots were performed to determine fi bronectin, transforming growth factor-β (TGF-β ), and PKC isoform levels.
RESULTS• Two weeks after PUUO surgery, hydronephrosis progressively developed. Tubular-interstitial fi brosis, collagen deposition and fi bronectin expression were increased.• PUUO also activated the expression of PKC α and PKC β and the translocation of PKCs from cell cytosol to cell membranes.• Treatment with PKCI signifi cantly decreased PKC α and PKC β expression and translocation in the renal cortex.• Treatment with PKCI also reduced the severity of hydronephrosis, decreased both glomerular and tubular cell apoptosis and mitosis, and attenuated the collagen and fi bronectin accumulation in renal interstitium.
CONCLUSIONS• Renal tubular apoptosis and interstitial fi brosis after obstructive nephropathy are associated with PKC α and PKC β activation.• The PKCI, chelerythrine, is capable of decreasing PKC expression and translocation in the renal cortex, suggesting that this inhibitor may have therapeutic potential in the protection of renal function in the fi rst few weeks after PUUO surgery.